Eli Lilly Co. released results from a study this week showing that its drug, Taltz, was better at treating psoriatic arthritis than Humira.
Humira, made by AbbVie, is the top-selling drug in the world and is indicated for several conditions including psoriasis, Crohn’s disease and ulcerative colitis.
Lilly’s study focused on psoriatic arthritis, which occurs in some psoriasis patients. Taltz was shown to be just as effective as Humira at reducing disease activity. But the drug performed better than Humira at clearing skin completely.
These results come as AbbVie prepares for multiple threats to Humira’s market dominance including a number of biosimilars that will enter the market soon.
Lilly said it hopes the results will prompt more doctors to prescribe Taltz, which was approved for plaque psoriasis in 2016, over Humira. The company said it will release the full details of the study in 2019.
Read the full Reuters report.